Oncolytics Biotech Inc. - Common Shares (ONCY)
ONCY moved a median of -0.06% 30 minutes after news, and 0.00% by the close. How ONCY actually reacts to news — the realized, point-in-time move the market made, measured across 530 labeled events over the last three years with zero look-ahead.
ONCY’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 41% | 515 |
| 30-min | -0.06% | 43% | 530 |
| 60-min | 0.00% | 49% | 530 |
| to close | 0.00% | 47% | 523 |
| Middle 50% of ONCY reactions | -1.77% to +1.41% |
|---|---|
| Median reaction (30-min) | -0.06% |
| Measured reactions | 530 |
Half of all Oncolytics Biotech Inc. - Common Shares news events land between -1.77% and +1.41% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when ONCY moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to ONCY's baseline. Nothing else.
Recent ONCY events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 8-K ONCOLYTICS BIOTECH INC For: Oct 12 | SEC filing · Form 8-K | SEC EDGAR | -3.93% | +0.20% | |
| Oncolytics Biotech® Secures Patent Protection to Late 2040s and Provides Intellectual Property Portfolio Update | Press release | GlobeNewswire | -3.93% | +0.20% | |
| Form DEF 14A ONCOLYTICS BIOTECH INC For: Dec 31 | SEC filing · Form DEF | SEC EDGAR | +0.00% | +0.98% | |
| Form DEFA14A ONCOLYTICS BIOTECH INC | SEC filing · Form DEFA14A | SEC EDGAR | +0.00% | +0.98% | |
| Form 8-K ONCOLYTICS BIOTECH INC For: Sep 29 | SEC filing · Form 8-K | SEC EDGAR | +0.27% | +0.97% | |
| Oncolytics Biotech® Announces Publication Demonstrating Pelareorep Creates Immune Responses in Liver Cancer That Make Tumors Susceptible to Immunotherapy | Press release | GlobeNewswire | -0.30% | +0.67% | |
| Form 8-K ONCOLYTICS BIOTECH INC For: Sep 28 | SEC filing · Form 8-K | SEC EDGAR | +0.94% | -3.36% | |
| Oncolytics Biotech® Reports Accelerating Enrollment in Randomized REO 033 RAS-Mutant, MSS Colorectal Cancer Study | Press release | GlobeNewswire | -0.72% | -3.91% | |
| Form 8-K ONCOLYTICS BIOTECH INC For: Sep 10 | SEC filing · Form 8-K | SEC EDGAR | +2.29% | -2.49% | |
| Oncolytics Biotech® Announces Positive Preclinical Results Combining Pelareorep with a Pan-RAS Inhibitor in Colorectal Cancer | Press release | GlobeNewswire | +2.29% | -2.49% | |
| Form 8-K ONCOLYTICS BIOTECH INC For: Aug 18 | SEC filing · Form 8-K | SEC EDGAR | +2.02% | +3.02% | |
| Oncolytics Biotech® Aligns with FDA on Registrational Path for Second-Line RAS-Mutant MSS Colorectal Cancer | Press release | GlobeNewswire | +2.02% | +3.02% | |
| Form 10-Q ONCOLYTICS BIOTECH INC For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -3.56% | -4.76% | |
| Form 8-K ONCOLYTICS BIOTECH INC For: Jul 20 | SEC filing · Form 8-K | SEC EDGAR | -0.14% | -0.13% | |
| Form 8-K ONCOLYTICS BIOTECH INC For: Jul 20 | SEC filing · Form 8-K | SEC EDGAR | +3.49% | -1.16% | |
| Oncolytics Biotech® Receives Fast Track Designation for Pelareorep in Second-Line and Later Anal Cancer | Press release | GlobeNewswire | +3.49% | -1.16% | |
| Form 8-K ONCOLYTICS BIOTECH INC For: Jul 13 | SEC filing · Form 8-K | SEC EDGAR | +10.15% | -1.14% | |
| Oncolytics Biotech® Reports FDA Regulatory Milestone and Strong Clinical Progress in Randomized RAS-Mutant MSS Colorectal Cancer Trial | Press release | GlobeNewswire | +10.15% | -1.14% | |
| Form 8-K ONCOLYTICS BIOTECH INC For: Jul 06 | SEC filing · Form 8-K | SEC EDGAR | +6.44% | +15.00% | |
| Form 8-K ONCOLYTICS BIOTECH INC For: Jun 16 | SEC filing · Form 8-K | SEC EDGAR | +2.52% | +7.90% | |
| Oncolytics Biotech® Secures New U.S. Patent Protecting Commercial Manufacturing of Pelareorep into 2044 | Press release | GlobeNewswire | +2.52% | +7.90% | |
| Form 8-K ONCOLYTICS BIOTECH INC For: Jun 02 | SEC filing · Form 8-K | SEC EDGAR | -3.61% | -16.43% | |
| Oncolytics Biotech® Announces Appointment of Steve Glover to Board of Directors and Promotion of John McAdory to Chief Operating Officer | Press release | GlobeNewswire | -3.61% | -16.43% | |
| Form 8-K ONCOLYTICS BIOTECH INC For: Jun 01 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -7.83% | |
| Oncolytics Biotech® Announces Positive Initial Preclinical Findings Supporting Further Evaluation of Pelareorep in Combination with RAS-Targeted Approaches | Press release | GlobeNewswire | +0.00% | -7.83% | |
| From Ambrx to Oncolytics: Why Jared Kelly Believes the Market May Be Missing the Bigger Oncology Story | Press release | ACCESS Newswire | -0.79% | -1.17% | |
| Form 8-K ONCOLYTICS BIOTECH INC For: May 22 | SEC filing · Form 8-K | SEC EDGAR | -0.65% | +0.53% | |
| Oncolytics Biotech® to Present Data at ASCO 2026 Reinforcing Pelareorep’s Potential Across Gastrointestinal Tumors | Press release | GlobeNewswire | -0.65% | +0.53% | |
| Form 10-Q ONCOLYTICS BIOTECH INC For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -2.30% | -2.30% | |
| Form 8-K ONCOLYTICS BIOTECH INC For: May 04 | SEC filing · Form 8-K | SEC EDGAR | +2.25% | +4.22% | |
| Oncolytics Biotech® Reports Durable Responses in Second-Line RAS-Mutant MSS Colorectal Cancer | Press release | GlobeNewswire | +2.25% | +4.22% | |
| Form 8-K ONCOLYTICS BIOTECH INC For: Apr 27 | SEC filing · Form 8-K | SEC EDGAR | -8.12% | -17.20% | |
| Oncolytics Aligns with FDA on Planned Pivotal Anal Cancer Study | Press release | GlobeNewswire | -8.12% | -17.20% | |
| Form AW ONCOLYTICS BIOTECH INC | SEC filing · Form AW | SEC EDGAR | +1.26% | +13.24% | |
| Form F-10POS ONCOLYTICS BIOTECH INC | SEC filing · Form F-10POS | SEC EDGAR | +1.26% | +13.24% | |
| Form 8-K ONCOLYTICS BIOTECH INC For: Apr 06 | SEC filing · Form 8-K | SEC EDGAR | +3.07% | +0.43% | |
| Form EFFECT ONCOLYTICS BIOTECH INC | SEC filing · Form EFFECT | SEC EDGAR | +3.07% | +0.43% | |
| Form F-10POS ONCOLYTICS BIOTECH INC | SEC filing · Form F-10POS | SEC EDGAR | -1.96% | -0.86% | |
| Oncolytics Biotech® Announces Type C FDA Meeting to Discuss Single-arm Registrational Pathway for Pelareorep in Anal Cancer | Press release | GlobeNewswire | +3.07% | +0.43% | |
| Form EFFECT ONCOLYTICS BIOTECH INC | SEC filing · Form EFFECT | SEC EDGAR | +1.10% | +4.39% | |
| Form 8-K ONCOLYTICS BIOTECH INC For: Mar 31 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +9.42% | |
| Form F-10POS ONCOLYTICS BIOTECH INC | SEC filing · Form F-10POS | SEC EDGAR | +0.00% | +9.42% | |
| Form POS AM ONCOLYTICS BIOTECH INC | SEC filing · Form POS | SEC EDGAR | +0.00% | +9.42% | |
| Form S-3 ONCOLYTICS BIOTECH INC | SEC filing · Form S-3 | SEC EDGAR | +0.00% | +9.42% | |
| Form S-8 ONCOLYTICS BIOTECH INC | SEC filing · Form S-8 | SEC EDGAR | +0.00% | +9.42% | |
| Form S-8 POS ONCOLYTICS BIOTECH INC | SEC filing · Form S-8 | SEC EDGAR | +0.00% | +9.42% | |
| Oncolytics Biotech® Completes Domicile Change to the United States | Press release | GlobeNewswire | +0.00% | +9.42% | |
| Form 10-K ONCOLYTICS BIOTECH INC For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +5.88% | +4.79% | |
| Form 8-K ONCOLYTICS BIOTECH INC For: Mar 17 | SEC filing · Form 8-K | SEC EDGAR | -0.11% | -2.15% | |
| Combination Therapies Reshape Oncology: A $748B Market Shifts Standard of Care | Press release | Canada Newswire | -0.01% | +3.56% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the ONCY section they belong to.
Where else ONCY is measured.
ONCY earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| BIOSTAGE INC NEW (BSTG) | 532 | 0.00% | 22% |
| OBALON THERAPEUTICS (OBLN) | 532 | -0.09% | 42% |
| Dr. Reddy's Laboratories Ltd (RDY) | 528 | 0.00% | 47% |
| LOXO ONCOLOGY (LOXO) | 526 | 0.00% | 49% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Oncolytics Biotech Inc. - Common Shares's median reaction calculated?
Every labeled ONCY news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 530 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 43% of ONCY's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does ONCY's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.